Search results
Showing 331 to 345 of 721 results for innovative
PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)
NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.
View recommendations for TA274Show all sections
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adults after 2 or more treatments.
Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor.
Naldemedine for treating opioid-induced constipation (TA651)
Evidence-based recommendations on naldemedine (Rizmoic) for treating opioid-induced constipation in adults who have had laxative treatment.
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)
Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)
NICE has developed a medtech innovation briefing (MIB) on remote ECG interpretation consultancy services for cardiovascular disease .
Tegaderm CHG securement dressing for vascular access sites (MIB231)
NICE has developed a medtech innovation briefing (MIB) on Tegaderm CHG securement dressing for vascular access sites .